Initial patient enrollment anticipated during first quarter of 2025White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to begin during the first quarter of 2025. The Investigational Device Exemption (IDE) application for the pivotal study of the Acclaim® Fully Implanted Cochlear Implant was approved by the U.S. Food and Drug Administration (FDA) last month. The Acclaim CI is a fully impl

WHITE BEAR LAKE, Minnesota , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on providing hearing loss suffers with innovative solutions today announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on November 25, 2024. The title of the patent is Combination Hearing Aid and Cochlear Implant System. This patent relates to updating a transfer function associated with an implanted signal processor of a cochlear implant system to compensate for operation of an external auditory aid device, such as a hearing aid, that affects a stimulus received at an input

WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous

Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant WHITE BEAR LAKE, Minnesota , Nov. 12, 2024 (GLOBE NEWSWIRE) --  Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential benefits of the Company's investigational fully implanted Acclaim® Cochlear Implant (Acclaim CI). The paper, titled, "Early Hearing Outcomes and Audiological Experiences with a Novel Fully Implanted Cochlear Implant," discusses the initial result

WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled," Implantable Modular Cochlear Implant System with Communication System and Network." The patent relates to a modular cochlear implant system configured to receive input signals from an implantable source and a wireless receiving device and output a stimulation signal based on the received input signals and a programmable mixing ratio representative of the relative contributions of the input signals to th

The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients WHITE BEAR LAKE, Minnesota, Nov. 01, 2024 (GLOBE NEWSWIRE) --  Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces that its Investigational Device Exemption (IDE) application for its pivotal study of the Acclaim® Fully Implanted Cochlear Implant has been approved by the U.S. Food and Drug Administration (FDA). The Acclaim® technology includes an implanted sensor designed to leverage the natural anatomy of the ear to capture sound, making it different from

Twelve Members of the Independence Through Enhancement of Medicare and Medicaid (ITEM) Coalition Sign Letter to CMS Seeking Clarification of Prior Decision Making and Action to Bring Novel Hearing Technology to Medicare Beneficiaries WHITE BEAR LAKE, Minnesota, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, expresses gratitude to the Independence Through Enhancement of Medicare and Medicaid ("ITEM") Coalition and the twelve ITEM member signatories for sending a strong letter to CMS supporting a reconsideration of the benefit category for fully implanted active middle ear he

WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event:                                                  LD Micro Main Event XVII Presentation Date:                            Tuesday, October 29, 2024 Time:                                                   12:00 PM Pacific Time Register

The Esteem® device is the only totally implantable active middle ear implant with FDA Approval, allowing the Company to be the first to capitalize on the new codes WHITE BEAR LAKE, Minnesota, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Envoy Medical, Inc. (NASDAQ:COCH), a market leader in fully implanted hearing devices, today announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has approved five Category III CPT codes for totally implantable active middle ear implants (AMEI), a crucial development for the Company's already FDA-approved Esteem® product. This marks the first time that there will be CPT codes for totally implantable active midd

Performance of COCH after de-SPAC sixty day "washout" period among leaders in peer group and Envoy Medical bullish on its long-term strategy WHITE BEAR LAKE, Minnesota , Oct. 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today commemorates its one-year anniversary trading as a public company. On September 29, 2023, the formerly private Envoy Medical merged with Anzu Special Purpose Acquisition Corp I, creating the now publicly traded Envoy Medical. COCH began trading on the Nasdaq Capital Market on October 2, 2023.   "Over the last year, we have made significant progress t

4 - Envoy Medical, Inc. (0001840877) (Issuer)

4 - Envoy Medical, Inc. (0001840877) (Issuer)

Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50